Yongjun Sui

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. pmc TLR agonists and/or IL-15 adjuvanted mucosal SIV vaccine reduced gut CD4⁺ memory T cell loss in SIVmac251-challenged rhesus macaques
    Yongjun Sui
    Vaccine Branch, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892, United States
    Vaccine 30:59-68. 2011
  2. pmc Innate and adaptive immune correlates of vaccine and adjuvant-induced control of mucosal transmission of SIV in macaques
    Yongjun Sui
    Vaccine Branch, Biostatistics and Data Management Section, and Laboratory of Experimental Immunology, National Cancer Institute, and Laboratory of Host Defenses and Laboratory of Molecular Immunology, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 107:9843-8. 2010
  3. pmc IL-15 ex vivo overcomes CD4+ T cell deficiency for the induction of human antigen-specific CD8+ T cell responses
    Huifeng Yu
    Vaccine Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    J Leukoc Biol 90:205-14. 2011
  4. pmc Comparative analysis of SIV-specific cellular immune responses induced by different vaccine platforms in rhesus macaques
    Antonio Valentin
    Human Retrovirus Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, USA
    Clin Immunol 155:91-107. 2014
  5. pmc Vaginal type-II mucosa is an inductive site for primary CD8⁺ T-cell mucosal immunity
    Yichuan Wang
    Vaccine Branch, Center for Cancer Research, National Cancer Institute, National Institute of Health, Bethesda, Maryland 20892, USA
    Nat Commun 6:6100. 2015
  6. pmc Immune targeting of PD-1(hi) expressing cells during and after antiretroviral therapy in SIV-infected rhesus macaques
    Diego A Vargas-Inchaustegui
    Vaccine Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Virology 447:274-84. 2013
  7. pmc Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice
    Qing Zhu
    Vaccine Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    J Clin Invest 120:607-16. 2010
  8. pmc Large intestine-targeted, nanoparticle-releasing oral vaccine to control genitorectal viral infection
    Qing Zhu
    Vaccine Branch, Center for Cancer Research, National Cancer Institute, US National Institutes of Health, Bethesda, Maryland, USA Department of Oncology, Air Force General Hospital, Beijing, China
    Nat Med 18:1291-6. 2012
  9. pmc Nonhuman primate models for HIV/AIDS vaccine development
    Yongjun Sui
    Vaccine Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland These authors contributed equally
    Curr Protoc Immunol 102:Unit 12.14.. 2013
  10. pmc Humoral immunity induced by mucosal and/or systemic SIV-specific vaccine platforms suggests novel combinatorial approaches for enhancing responses
    Diego A Vargas-Inchaustegui
    Immune Biology of Retroviral Infection Section, Vaccine Branch, CCR, NCI, NIH, Bethesda, MD 20892, United States
    Clin Immunol 153:308-22. 2014

Collaborators

  • Jay A Berzofsky
  • Genoveffa Franchini
  • Igor M Belyakov
  • Marjorie Robert-Guroff
  • Barbara K Felber
  • Dennis M Klinman
  • Masaki Terabe
  • Shingo Kato
  • W Strober
  • Ranajit Pal
  • Diego A Vargas-Inchaustegui
  • Yichuan Wang
  • Alison E Hogg
  • Qing Zhu
  • Antonio Valentin
  • Namal P M Liyanage
  • Blake Frey
  • L Jean Patterson
  • Margherita Rosati
  • Shari N Gordon
  • George N Pavlakis
  • Poonam Pegu
  • Guy R Pilkington
  • Jenifer Bear
  • Niranjan Y Sardesai
  • Viraj Kulkarni
  • Candido Alicea
  • Steven G Reed
  • Thorsten Demberg
  • Katherine McKinnon
  • Janet Dipasquale
  • Susan Gagnon
  • Huifeng Yu
  • Jason C Steel
  • John C Morris
  • David J Venzon
  • David C Montefiori
  • Jinyao Li
  • Thomas Musich
  • Iskra Tuero
  • Venkatramanan Mohanram
  • Monica Vaccari
  • David Venzon
  • Solomon Langermann
  • Peng Xiao
  • Linda Liu
  • Lauren Hudacik
  • Eun M Lee
  • Egidio Brocca-Cofano
  • Russell J Mumper
  • Zijian Wang
  • Barbel Eppler
  • James Talton
  • Robert C Waters
  • James Kirk
  • Guofeng Zhang
  • Tshaka Cunningham
  • Amiran Dzutsev
  • Abdul Tawab-Amiri
  • Robert Yarchoan
  • Marianna Sabatino
  • Karen Aleman
  • Colt Egelston

Detail Information

Publications10

  1. pmc TLR agonists and/or IL-15 adjuvanted mucosal SIV vaccine reduced gut CD4⁺ memory T cell loss in SIVmac251-challenged rhesus macaques
    Yongjun Sui
    Vaccine Branch, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892, United States
    Vaccine 30:59-68. 2011
    ..Overall, these data highlight one unrecognized role of adjuvant in HIV vaccine development, and show that vaccines can produce a surprising discordance between CD4(+) T cell levels and SIV viral load...
  2. pmc Innate and adaptive immune correlates of vaccine and adjuvant-induced control of mucosal transmission of SIV in macaques
    Yongjun Sui
    Vaccine Branch, Biostatistics and Data Management Section, and Laboratory of Experimental Immunology, National Cancer Institute, and Laboratory of Host Defenses and Laboratory of Molecular Immunology, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 107:9843-8. 2010
    ..Thus, strategic use of molecular adjuvants can provide better mucosal protection through induction of both innate and adaptive immunity...
  3. pmc IL-15 ex vivo overcomes CD4+ T cell deficiency for the induction of human antigen-specific CD8+ T cell responses
    Huifeng Yu
    Vaccine Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    J Leukoc Biol 90:205-14. 2011
    ..These results suggest that IL-15 may be useful in the development of therapeutic and preventive vaccines against cancers and viral infections in patients defective in CD4(+) Th cell...
  4. pmc Comparative analysis of SIV-specific cellular immune responses induced by different vaccine platforms in rhesus macaques
    Antonio Valentin
    Human Retrovirus Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, USA
    Clin Immunol 155:91-107. 2014
    ..The cellular and reported humoral immune response data suggest that combination of DNA and viral vectors elicits a balanced immunity with strong and durable responses able to disseminate into relevant mucosal sites. ..
  5. pmc Vaginal type-II mucosa is an inductive site for primary CD8⁺ T-cell mucosal immunity
    Yichuan Wang
    Vaccine Branch, Center for Cancer Research, National Cancer Institute, National Institute of Health, Bethesda, Maryland 20892, USA
    Nat Commun 6:6100. 2015
    ....
  6. pmc Immune targeting of PD-1(hi) expressing cells during and after antiretroviral therapy in SIV-infected rhesus macaques
    Diego A Vargas-Inchaustegui
    Vaccine Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Virology 447:274-84. 2013
    ..Continued immune modulation targeting PD-1(hi) cells during and post-ART helps maintain lower viremia, keeps a favorable T cell/Treg repertoire and modulates antigen-specific responses. ..
  7. pmc Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice
    Qing Zhu
    Vaccine Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    J Clin Invest 120:607-16. 2010
    ..Therefore, selective TLR ligand combinations can increase protective efficacy by increasing the quality rather than the quantity of T cell responses...
  8. pmc Large intestine-targeted, nanoparticle-releasing oral vaccine to control genitorectal viral infection
    Qing Zhu
    Vaccine Branch, Center for Cancer Research, National Cancer Institute, US National Institutes of Health, Bethesda, Maryland, USA Department of Oncology, Air Force General Hospital, Beijing, China
    Nat Med 18:1291-6. 2012
    ..Therefore, using this oral vaccine delivery system to target the large intestine, but not the small intestine, may represent a feasible new strategy for immune protection of rectal and vaginal mucosa. ..
  9. pmc Nonhuman primate models for HIV/AIDS vaccine development
    Yongjun Sui
    Vaccine Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland These authors contributed equally
    Curr Protoc Immunol 102:Unit 12.14.. 2013
    ..Understanding how to effectively use this valuable model will greatly increase the likelihood of finding a successful vaccine for HIV...
  10. pmc Humoral immunity induced by mucosal and/or systemic SIV-specific vaccine platforms suggests novel combinatorial approaches for enhancing responses
    Diego A Vargas-Inchaustegui
    Immune Biology of Retroviral Infection Section, Vaccine Branch, CCR, NCI, NIH, Bethesda, MD 20892, United States
    Clin Immunol 153:308-22. 2014
    ..Our results suggest that combined RepAd priming with ALVAC/Env or DNA&Env regimen boosting might induce potent, functional, long-lasting systemic and mucosal SIV-specific antibodies. ..